| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 4,988 | 6,822 | 7,006 | 7,796 | 5,401 |
| Sales Growth | -26.88% | -2.63% | -10.13% | +44.34% | -37.37% |
| Net Income | 1,995 | -1,947 | -590 | -582 | -114 |
| Net Income Growth | +202.47% | -230.00% | -1.37% | -410.53% | +60.69% |
Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
InnoCan Pharma Corp is a engaged in the development, manufacture, and marketing of cosmetic products. The company has two segments: Online sales - Sky Global operations, which engages in the development of non-CBD personal care and beauty products in the United States for online platforms such as Amazon, and other e-commerce retail sales. Other operations - the development of several drug delivery platforms, combining cannabinoids with other pharmaceutical ingredients as well as the development and sale of CBD-integrated topical products.
Fiscal Year End Date: 12/31